特殊ジェネリックの世界市場レポート 2025年

特殊ジェネリックの市場規模は今後数年で急成長が見込まれます。2029年には年間平均成長率（CAGR）15.1％で1,897億2,000万米ドルに成長します。予測期間の成長は、バイオシミラー市場の拡大、複雑なジェネリック医薬品開発の重視、特殊ジェネリック注射剤への注目の高まり、特殊ジェネリック製造における3Dプリンティングの採用、新興市場における特殊ジェネリックの成長に起因しています。予測期間における主な動向としては、個別化・標的化特殊ジェネリック、ジェネリック医薬品開発における戦略的パートナーシップと提携、乱用抑止製剤の開発重視、特殊ジェネリックにおけるデジタルヘルス技術の統合、複雑なジェネリック医薬品の承認加速に向けた規制当局の取り組みなどが挙げられます。

慢性疾患の増加が特殊ジェネリック医薬品市場の需要を押し上げると予測されます。慢性疾患は、管理・コントロールが可能なものもありますが、多くの場合不治の病となる長期的な病気です。ライフスタイルの変化、食習慣の乱れ、不適切な体重管理などの要因が慢性疾患の蔓延に寄与しており、慢性疾患の長期化によってがんのリスクが高まるものもあります。このような疾病の罹患率の増加は、複雑な慢性疾患の治療に対する特殊ジェネリックの必要性を増幅させています。例えば、2022年9月、スイスに本部を置く国連の専門機関である世界保健機関（WHO）は、非感染性疾患（NCDs）または慢性疾患による死亡の74％を占める年間4,100万人の死亡が世界的に発生していると報告しました。その内訳は、心血管疾患による死亡が1,790万人、がんによる死亡が930万人、慢性呼吸器疾患による死亡が410万人、糖尿病による死亡が200万人です。そのため、慢性疾患の急増が特殊ジェネリック市場の成長に拍車をかけています。

人口の高齢化は、将来的に特殊ジェネリック市場を促進すると予想されます。高齢化」とは、社会における高齢者の割合の増加を特徴とする人口動態の変化を指します。特殊ジェネリックは、術後の疼痛、急性感染症、短期的な疼痛緩和など、高齢者に多い急性症状に対処するために特別に処方された医薬品です。これにより、ヘルスケアコストを管理しながら、高齢化社会に効果的な治療の選択肢を提供することができます。2022年10月の世界保健機関（WHO）の予測によると、2030年には世界の6人に1人が60歳以上の高齢者となり、その数は14億人に達します。2050年には、世界の60歳以上の人口は2倍の21億人になると予想されています。したがって、高齢化は特殊ジェネリック医薬品市場の重要な促進要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の特殊ジェネリック PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の特殊ジェネリック市場：成長率分析
• 世界の特殊ジェネリック市場の実績：規模と成長, 2019-2024
• 世界の特殊ジェネリック市場の予測：規模と成長, 2024-2029, 2034F
• 世界の特殊ジェネリック総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の特殊ジェネリック市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注入
• 経口
• その他の投与経路
• 世界の特殊ジェネリック市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オンコロジー
• 自己免疫疾患
• 感染症
• その他の適応症
• 世界の特殊ジェネリック市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小売薬局
• 専門薬局
• 病院薬局
• 世界の特殊ジェネリック市場、注射剤のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内（IV）注射剤
• 筋肉内（IM）注射剤
• 皮下注射剤
• 世界の特殊ジェネリック市場、口腔のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 錠剤
• カプセル
• 液体製剤
• 世界の特殊ジェネリック市場、その他の投与経路のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外用
• 経皮
• 吸入

第7章 地域別・国別分析

• 世界の特殊ジェネリック市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の特殊ジェネリック市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 特殊ジェネリック市場：競合情勢
• 特殊ジェネリック市場：企業プロファイル
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Endo International plc Overview, Products and Services, Strategy and Financial Analysis
  • Akorn Operating Company LLC Overview, Products and Services, Strategy and Financial Analysis
  • Mallinckrodt Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
  • Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Fresenius Kabi Brasil Ltda
• STADA Arzneimittel AG
• Cipla Limited
• Lupin Ltd
• Aurobindo Pharma Limited
• Aspen Pharmacare Holdings Limited
• Pfizer Inc.
• Accord Healthcare Limited
• Amneal Pharmaceuticals Inc.
• Sandoz International GmbH
• Zydus Lifesciences Ltd.
• Torrent Pharmaceuticals Ltd.
• Perrigo Company plc
• Impax Laboratories Inc.
• Par Pharmaceutical Companies Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 特殊ジェネリック市場2029：新たな機会を提供する国
• 特殊ジェネリック市場2029：新たな機会を提供するセグメント
• 特殊ジェネリック市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Specialty generics refer to generic versions of drugs designed to replicate expensive, intricate, or high-touch generic medications. Managing specialty generics requires substantial service participation. This category encompasses biologics and biosimilars, each with distinct regulatory routes. Specialty medications, in general, are commonly used to treat various conditions such as malignancies, rheumatoid arthritis, and multiple sclerosis.

Specialty generics are administered through various routes, including injectables, oral, and others. The injectables route involves diverse methods of drug administration such as intravenous, subcutaneous, intradermal, intraperitoneal, intramuscular, and others. This is applicable in the treatment of medical conditions ranging from cancer to autoimmune disorders. Drug injection typically involves the use of a hollow hypodermic needle to introduce a substance into the bloodstream. Specialty generics find applications in indications like oncology, autoimmune diseases, infectious diseases, and others. These medications are distributed through multiple channels, including retail pharmacies, specialty pharmacies, and hospital pharmacies.

The specialty generics market research report is one of a series of new reports from The Business Research Company that provides specialty generics market statistics, including specialty generics industry global market size, regional shares, competitors with a specialty generics market share, detailed specialty generics market segments, market trends and opportunities, and any further data you may need to thrive in the specialty generics industry. This specialty generics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The specialty generics market size has grown rapidly in recent years. It will grow from $95.87 billion in 2024 to $108.11 billion in 2025 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to patent expirations of brand-name drugs, growing demand for cost-effective alternatives, regulatory support for generic drug approvals, increasing healthcare cost pressures, rise in chronic diseases and aging population.

The specialty generics market size is expected to see rapid growth in the next few years. It will grow to $189.72 billion in 2029 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to expansion of biosimilars market, emphasis on complex generic drug development, increasing focus on specialty generic injectables, adoption of 3d printing in specialty generic manufacturing, growth of specialty generics in emerging markets. Major trends in the forecast period include personalized and targeted specialty generics, strategic partnerships and collaborations in generic drug development, focus on developing abuse-deterrent formulations, integration of digital health technologies in specialty generics, regulatory initiatives for accelerated approval of complex generics.

The increase in chronic diseases is projected to boost the demand for the specialty generic market. Chronic diseases are long-term illnesses that are often incurable, although some can be managed or controlled. Factors such as changing lifestyles, poor eating habits, and inadequate weight management contribute to the prevalence of chronic conditions, with some extended chronic illnesses heightening the risk of cancer. The rising incidence of these diseases amplifies the need for specialty generics to treat complex chronic conditions. For example, in September 2022, the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported that 41 million deaths annually-accounting for 74% of deaths from non-communicable diseases (NCDs) or chronic diseases-occur globally. This includes 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Therefore, the surge in chronic diseases is fueling the growth of the specialty generic market.

The aging population is expected to propel the specialty generic market in the future. The term 'aging population' denotes the demographic shift characterized by a rising proportion of elderly individuals in a society. Specialty generics are specifically formulated pharmaceuticals designed to address acute conditions prevalent in the elderly, such as postoperative pain, acute infections, or short-term pain relief. This ensures effective treatment options for the aging population while managing healthcare costs. According to the World Health Organization's projections in October 2022, by 2030, one out of every six individuals globally will be 60 years or older, reaching 1.4 billion. By 2050, the global population of individuals aged 60 and older is expected to double to 2.1 billion. Therefore, the aging population is a significant driver for the specialty generic market.

Major companies in the specialty generic market are obtaining approvals for medications like Lisdexamfetamine Dimesylate to address critical medical needs. Approval in specialty generics refers to the regulatory authorization granted to pharmaceutical products that are bioequivalent and therapeutically equivalent to brand-name specialty drugs. In August 2023, Mallinckrodt plc, an Ireland-based specialty pharmaceutical company, received FDA approval for Lisdexamfetamine Dimesylate Capsules in SpecGx LLC Specialty Generics segment to treat Attention-Deficit/Hyperactivity Disorder (ADHD). Lisdexamfetamine Dimesylate, a federally controlled substance (CII), is used for ADHD and other indications.

Major companies in the specialty generic market are introducing new products to offer more affordable alternatives. In March 2022, Teva Pharmaceutical Industries Ltd, an Israel-based pharmaceutical company, launched the first generic version of REVLIMID (lenalidomide) in the US, available in 5mg, 10mg, 15mg, and 25mg capsules. REVLIMID is prescribed for adults with multiple myeloma (MM) and is used either in combination with dexamethasone or as a maintenance treatment post-autologous hematopoietic stem cell transplantation.

In October 2022, Aspire Pharma, a UK-based pharmaceutical company, acquired Morningside Pharmaceuticals and Morningside Healthcare, including its subsidiaries like Morningside Healthcare (India), for an undisclosed amount. This strategic acquisition aims to expand Aspire Pharma's market position by combining complementary product portfolios, providing added talent, an increased in-market range, and an industry-leading pipeline, positioning the company as a premier specialty generic pharmaceutical organization.

Major companies operating in the specialty generics market include Teva Pharmaceutical Industries Ltd., Endo International plc, Akorn Operating Company LLC, Mallinckrodt Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Fresenius Kabi Brasil Ltda, STADA Arzneimittel AG, Cipla Limited, Lupin Ltd, Aurobindo Pharma Limited, Aspen Pharmacare Holdings Limited, Pfizer Inc., Accord Healthcare Limited, Amneal Pharmaceuticals Inc., Sandoz International GmbH, Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Perrigo Company plc, Impax Laboratories Inc., Par Pharmaceutical Companies Inc., Alvogen, Alkem Laboratories Ltd., Wockhardt Ltd., Strides Pharma Science Limited, Indoco Remedies Ltd., Unichem Laboratories Ltd., Alembic Pharmaceuticals Ltd., Jubilant Life Sciences Ltd.

North America was the largest region in the specialty generics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specialty generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the specialty generics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The specialty generics market consists of sales of biologics and biosimilars. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Specialty Generics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on specialty generics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for specialty generics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The specialty generics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Route Of Administration: Injectables; Oral; Other Route Of Administration
• 2) By Indication: Oncology; Autoimmune Diseases; Infectious Diseases; Other Indication
• 3) By Distribution Channel: Retail Pharmacies; Specialty Pharmacies; Hospital Pharmaciesx
• Subsegments:
• 1) By Injectables: Intravenous (IV) Injectables; Intramuscular (IM) Injectables; Subcutaneous (SC) Injectables
• 2) By Oral: Tablets; Capsules; Liquid Formulations
• 3) By Other Route Of Administration: Topical; Transdermal; Inhalation
• Companies Mentioned: Teva Pharmaceutical Industries Ltd.; Endo International plc; Akorn Operating Company LLC; Mallinckrodt Pharmaceuticals; Dr. Reddy's Laboratories Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Specialty Generics Market Characteristics

3. Specialty Generics Market Trends And Strategies

4. Specialty Generics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Specialty Generics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Specialty Generics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Specialty Generics Market Growth Rate Analysis
• 5.4. Global Specialty Generics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Specialty Generics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Specialty Generics Total Addressable Market (TAM)

6. Specialty Generics Market Segmentation

• 6.1. Global Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectables
• Oral
• Other Route Of Administration
• 6.2. Global Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Other Indication
• 6.3. Global Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retail Pharmacies
• Specialty Pharmacies
• Hospital Pharmacies
• 6.4. Global Specialty Generics Market, Sub-Segmentation Of Injectables, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous (IV) Injectables
• Intramuscular (IM) Injectables
• Subcutaneous (SC) Injectables
• 6.5. Global Specialty Generics Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Capsules
• Liquid Formulations
• 6.6. Global Specialty Generics Market, Sub-Segmentation Of Other Route Of Administration, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical
• Transdermal
• Inhalation

7. Specialty Generics Market Regional And Country Analysis

• 7.1. Global Specialty Generics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Specialty Generics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Specialty Generics Market

• 8.1. Asia-Pacific Specialty Generics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Specialty Generics Market

• 9.1. China Specialty Generics Market Overview
• 9.2. China Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Specialty Generics Market

• 10.1. India Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Specialty Generics Market

• 11.1. Japan Specialty Generics Market Overview
• 11.2. Japan Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Specialty Generics Market

• 12.1. Australia Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Specialty Generics Market

• 13.1. Indonesia Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Specialty Generics Market

• 14.1. South Korea Specialty Generics Market Overview
• 14.2. South Korea Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Specialty Generics Market

• 15.1. Western Europe Specialty Generics Market Overview
• 15.2. Western Europe Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Specialty Generics Market

• 16.1. UK Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Specialty Generics Market

• 17.1. Germany Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Specialty Generics Market

• 18.1. France Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Specialty Generics Market

• 19.1. Italy Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Specialty Generics Market

• 20.1. Spain Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Specialty Generics Market

• 21.1. Eastern Europe Specialty Generics Market Overview
• 21.2. Eastern Europe Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Specialty Generics Market

• 22.1. Russia Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Specialty Generics Market

• 23.1. North America Specialty Generics Market Overview
• 23.2. North America Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Specialty Generics Market

• 24.1. USA Specialty Generics Market Overview
• 24.2. USA Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Specialty Generics Market

• 25.1. Canada Specialty Generics Market Overview
• 25.2. Canada Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Specialty Generics Market

• 26.1. South America Specialty Generics Market Overview
• 26.2. South America Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Specialty Generics Market

• 27.1. Brazil Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Specialty Generics Market

• 28.1. Middle East Specialty Generics Market Overview
• 28.2. Middle East Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Specialty Generics Market

• 29.1. Africa Specialty Generics Market Overview
• 29.2. Africa Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Specialty Generics Market Competitive Landscape And Company Profiles

• 30.1. Specialty Generics Market Competitive Landscape
• 30.2. Specialty Generics Market Company Profiles
  • 30.2.1. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Endo International plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Akorn Operating Company LLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Mallinckrodt Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Specialty Generics Market Other Major And Innovative Companies

• 31.1. Fresenius Kabi Brasil Ltda
• 31.2. STADA Arzneimittel AG
• 31.3. Cipla Limited
• 31.4. Lupin Ltd
• 31.5. Aurobindo Pharma Limited
• 31.6. Aspen Pharmacare Holdings Limited
• 31.7. Pfizer Inc.
• 31.8. Accord Healthcare Limited
• 31.9. Amneal Pharmaceuticals Inc.
• 31.10. Sandoz International GmbH
• 31.11. Zydus Lifesciences Ltd.
• 31.12. Torrent Pharmaceuticals Ltd.
• 31.13. Perrigo Company plc
• 31.14. Impax Laboratories Inc.
• 31.15. Par Pharmaceutical Companies Inc.

32. Global Specialty Generics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Specialty Generics Market

34. Recent Developments In The Specialty Generics Market

35. Specialty Generics Market High Potential Countries, Segments and Strategies

• 35.1 Specialty Generics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Specialty Generics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Specialty Generics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer